Blood Cancer Discovery

Aims & Scope

Blood Cancer Discovery publishes high-quality Research Articles and Briefs representing major advances in basic, translational, and clinical research of leukemia, lymphoma, myeloma, and associated diseases.

The topics appropriate for coverage include but are not limited to the following: molecular and cellular features of pathogenesis, therapy response and relapse, transcriptional circuits, stem cells, differentiation, microenvironment, metabolism, immunity, mutagenesis, and clonal evolution.

These subjects are characterized in animal disease models as well as in high-dimensional clinical data landscapes.

The journal welcomes submissions on new pharmacological, biological, and living cell therapies; new diagnostic tools; prognostic, diagnostic, and pharmacodynamic biomarkers; and computational and machine learning approaches to personalized medicine, from preclinical proof of concept to clinical trials and real-world evidence.

As a forum for diverse ideas shaping future research directions, the journal will publish Reviews, Perspectives, and Commentaries on topics of broad interest in hematooncology.

View Aims & Scope

---

Metrics & Ranking

Impact Factor

Year	Value
2025	11.5
2024	11.50

Journal Rank

Year	Value
2024	369

Journal Citation Indicator

Year	Value
2024	1068

SJR (SCImago Journal Rank)

Year	Value
2024	4.316

Quartile

Year	Value
2024	Q1

---

---

Abstracting & Indexing

Journal is indexed in leading academic databases, ensuring global visibility and accessibility of our peer-reviewed research.

• Scopus
• Google Scholar
• Web of Science
• Medline
• PubMed
• Embase

---

Subjects & Keywords

Journal’s research areas, covering key disciplines and specialized sub-topics in Biochemistry, Genetics and Molecular Biology and Medicine, designed to support cutting-edge academic discovery.

---

Most Cited Articles

The Most Cited Articles section features the journal's most impactful research, based on citation counts. These articles have been referenced frequently by other researchers, indicating their significant contribution to their respective fields.

• Scalable Manufacturing of CAR T Cells for Cancer Immunotherapy

  Citation: 199

  Authors: Mohamed, Magdi, Steven A., Andrew D., Helen E., Peter, Brian G., Gerhard, Barbara

• Defining an Optimal Dual-Targeted CAR T-cell Therapy Approach Simultaneously Targeting BCMA and GPRC5D to Prevent BCMA Escape–Driven Relapse in Multiple Myeloma

  Citation: 169

  Authors: Carlos, Mette, Andrea V., Khong Y., Yunxin, William D., Terence J., Vladimir, Hans-Guido, Renier J., Eric L.

• Next-Generation Sequencing of Minimal Residual Disease for Predicting Relapse after Tisagenlecleucel in Children and Young Adults with Acute Lymphoblastic Leukemia

  Citation: 139

  Authors: Michael A., Xia, Shannon L., Theodore W., Muna, Susana, Michael W., Hidefumi, Gregory A., Tim, G. Doug, Peter, Andre, Jochen, Heather E., Creton, Kevin, Edward R., Karen, Harald J., Gabor, Stephan A.

• Mutational Landscape and Patterns of Clonal Evolution in Relapsed Pediatric Acute Lymphoblastic Leukemia

  Citation: 128

  Authors: Esmé, Zhaohui, Stephanie M., Željko, Jeremy Chase, Xiaotu, Michael N., Debbie, Maartje, Marjolijn C.J., Irina, Xin, Jian, Lei, Stanley, Deqing, Cheng, Guangchun, Yiping, Ying, Michael, Kelly, Jiangyan, Ruben, Francis, Ilaria, Kathryn G., Ji, Gang, Jing, John, Geoffrey, Scott R., Kim E., Ching-Hon, Jinghui, William E., Mary V., Jun J., Paul G., John E., Roland P., Charles G.

• Clinical Significance of Novel Subtypes of Acute Lymphoblastic Leukemia in the Context of Minimal Residual Disease–Directed Therapy

  Citation: 118

  Authors: Sima, John, Kathryn G., Deqing, Elaine, Hiroto, Jeffrey E., Raul C., Tanja A., Susana C., Seth E., Chunxu, Samuel W., Zhaohui, Jun J., Cheng, James R., Williams E., Mary V., Dario, Charles G., Ching-Hon

• Bortezomib Induces Anti–Multiple Myeloma Immune Response Mediated by cGAS/STING Pathway Activation

  Citation: 110

  Authors: Annamaria, Eugenio, Mehmet K., Cirino, Teru, Giada, Mariateresa, Stefano, Rao H., Srikanth, Kenneth, Yu-Tzu, Paul G., Dharminder, Tomasz, Ruben D., Nikhil C., Kenneth C.

• Revealing the Impact of Structural Variants in Multiple Myeloma

  Citation: 107

  Authors: Even H., Venkata D., Dominik, Kylee H., Benjamin, Eileen M., Cody, Patrick, Gunes, Malin, Daniel, Nicos, Luca, Daniel, Yanming, Ahmet, Niccolò, Elli, Kenneth C., Philippe, Hervé, Nikhil C., Jonathan J., Peter J., Gareth J., Ola, Francesco

• Blockade or Deletion of IFNγ Reduces Macrophage Activation without Compromising CAR T-cell Function in Hematologic Malignancies

  Citation: 104

  Authors: Stefanie R., Sonika, Rebecca C., Amanda A., Irene, Michael C., Trisha R., Mark B., Marc, Andrea, Harrison, Kevin A., Ashley, Kathleen M.E., Matthew J., Marcela V.

• T-cell Acute Lymphoblastic Leukemia: A Roadmap to Targeted Therapies

  Citation: 98

  Authors: Valentina, Jordy C.G., Kirsten, Rob, Jules P.P.

• A Phase Ib/II Study of Ivosidenib with Venetoclax ± Azacitidine in <i>IDH1</i>-Mutated Myeloid Malignancies

  Citation: 82

  Authors: Curtis A., Sanam, Zhihong, Tomoyuki, Yi June, Hidetaka, Sven, Niels Asger, Marlise R., Dzifa Y., Rebecca S.S., Nicholas J., Gautam, Tapan M., Lucia, George D., Prithviraj, Elias J., Farhad, Naval G., Guillermo, Hagop, Jacqueline S., Paresh, Koichi, Marina, Courtney D.

---